Aerosolized plus intravenous polymyxin B in comparison to intravenous polymyxin B alone for the management of HAP caused by carbapenem-resistant gram-negative bacteria: A prospective multicenter cohort study

被引：0

作者：

Zhang, Jingjing ^{[1
]}

Du, Linyun ^{[1
]}

Shi, Qindong ^{[2
]}

Li, Xinyu ^{[3
]}

Li, Jianying ^{[4
]}

Dong, Enxia ^{[5
]}

Guo, Hao ^{[6
]}

Zhang, Xiaoling ^{[1
]}

Hou, Yanli ^{[1
]}

Jin, Xuting ^{[1
]}

Li, Jiamei ^{[1
]}

Wang, Xiaochuang ^{[1
]}

Wang, Gang ^{[1
]}

机构：

[1] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Crit Care Med, Xian, Peoples R China

[2] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Crit Care Med, Xian, Peoples R China

[3] Xian Med Univ, Affiliated Hosp 2, Dept Crit Care Med, Xian, Peoples R China

[4] Xian Chest Hosp, Dept Resp & Crit Care Med, Xian, Peoples R China

[5] Xian Red Cross Hosp, Dept Crit Care Med, Xian, Peoples R China

[6] First Peoples Hosp Xianyang City, Dept Crit Care Med, Xianyang, Peoples R China

来源：

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2025年 / 65卷 / 02期

关键词：

Polymyxin B; Aerosolized; CRO; Pneumonia; Intensive care unit; ACINETOBACTER-BAUMANNII; COLISTIN; SUSCEPTIBILITY; ANTIBIOTICS; PNEUMONIAE; FAILURE;

D O I：

10.1016/j.ijantimicag.2024.107427

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Objectives: This study aimed to evaluate the clinical effectiveness of combined aerosolized (AER) and intravenous (IV) polymyxin B in managing patients with hospital-acquired pneumonia (HAP) caused by carbapenem-resistant gram-negative organism (CRO). Methods: This multicenter prospective cohort study was conducted across six intensive care units in municipal and above-municipal hospitals in Shaanxi, China, from January 1, 2021 to December 31, 2022. Patients with CRO pneumonia were categorized into the intravenous group (IV polymyxin B alone) and the combination group (AER plus IV polymyxin B). Primary outcomes included ICU mortality, 28-day mortality and bacterial clearance, while secondary outcomes included the duration of mechanical ventilation and length of ICU stay. Results: A total of 64 patients were included in the study, with 29 receiving AER plus IV polymyxin B and 35 receiving IV polymyxin B alone. On the seventh day of treatment, the combination group showed a significant reduction in the APACHE II score (17.86 +/- 5.03 vs. 19.17 +/- 11.02, P = 0.041) and procalcitonin levels (1.27 +/- 0.20 vs. 3.18 +/- 0.69, P < 0.001) compared to the intravenous group. Additionally, the combination group exhibited a higher bacterial eradication rate (62.1% vs. 42.9%), lower ICU mortality (27.6% vs. 37.1%), shorter duration of mechanical ventilation (371.39 +/- 68.97 h vs. 563.94 +/- 100.25 h), and reduced ICU stay (34.41 +/- 17.87 d vs. 35.03 +/- 21.66 d), although the differences were not statistically significant. Conclusions: In patients with CRO pneumonia, combination therapy resulted in significant reductions in APACHE II scores and procalcitonin, but did not lead to statistically significant improvements in clinical outcomes, compared to IV polymyxin B alone. (c) 2024 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

引用

页数：7

共 29 条

[1] Quartin A.A., Scerpella E.G., Puttagunta S., Et al., A comparison of microbiology and demographics among patients with healthcare-associated, hospital-acquired, and ventilator-associated pneumonia: a retrospective analysis of 1184 patients from a large, international study, BMC Infect Dis, 13, (2013)
[2] Zeng M., Xia J., Zong Z., Et al., Guidelines for the diagnosis, treatment, prevention and control of infections caused by carbapenem-resistant gram-negative bacilli, J Microbiol Immunol Infect, 56, pp. 653-671, (2023)
[3] Paul M., Carrara E., Retamar P., Et al., European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European society of intensive care medicine), Clin Microbiol Infect, 28, pp. 521-547, (2022)
[4] Nation R.L., Velkov T., Li J., Colistin and polymyxin B: peas in a pod, or chalk and cheese?, Clin Infect Dis, 59, pp. 88-94, (2014)
[5] pp. 868-885, (2020)
[6] Ni W., Shao X., Di X., Et al., In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: a systematic review and meta-analysis, Int J Antimicrob Agents, 45, pp. 8-18, (2015)
[7] Tsuji B.T., Pogue J.M., Zavascki A.P., Et al., International Consensus Guidelines for the Optimal Use of the Polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP), Pharmacotherapy, 39, pp. 10-39, (2
[8] Lu D., Mao W., Efficacy and safety of intravenous combined with aerosolised polymyxin versus intravenous polymyxin alone in the treatment of multidrug-resistant gram-negative bacterial pneumonia: a systematic review and meta-analysis, Heliyon, 9, (2023)
[9] Shi R., Fu Y., Gan Y., Et al., Use of polymyxin B with different administration methods in the critically ill patients with ventilation associated pneumonia: a single-center experience, Front Pharmacol, 14, (2023)
[10] Liu J., Shao M., Xu Q., Et al., Low-dose intravenous plus inhaled versus intravenous polymyxin B for the treatment of extensive drug-resistant gram-negative ventilator-associated pneumonia in the critical illnesses: a multi-center matched case–control study, Ann. Intensive Care, 12, (2022)

← 1 2 3 →